West Point pharmaceutical: Announcement on initial public offering and listing on GEM

Jilin Xidian pharmaceutical science and Technology Development Co., Ltd. initial public offering and listing on the gem announcement sponsor (lead underwriter): Haitong Securities Company Limited(600837) special note: according to the industry classification guidelines for listed companies (revised in 2012) of China Securities Regulatory Commission, the industry of Xidian pharmaceutical is "pharmaceutical manufacturing (C27)". As of February 8, 2022 (T-4), The average static P / E ratio of the industry released by China Securities Index Co., Ltd. in the latest month was 37.80 times. The issuance price of 22.55 yuan / share corresponds to the lower diluted P / E ratio of the issuer before and after deducting non recurring profits and losses in 2020, which is 42.95 times higher than the average static P / E ratio of the industry in the latest month released by China Securities Index Co., Ltd. on February 8 (T-4) 2022, with an excess range of 13.62%; It is 45.55 times lower than the average static P / E ratio of comparable companies after deducting non-profit in 2020. The issuer and the recommendation institution (lead underwriter) remind investors to pay full attention to the risk factors contained in the pricing marketization, know that the stock may fall below the issue price after listing, effectively improve the risk awareness, strengthen the value investment concept, avoid blind speculation, carefully study and judge the rationality of the issue pricing, and make rational investment decisions. Jilin West Point Pharmaceutical Technology Development Co., Ltd. (hereinafter referred to as "West Point pharmaceutical", "issuer" or "company") in accordance with the measures for the administration of securities issuance and underwriting (CSRC order [No. 144], hereinafter referred to as the "measures") issued by the China Securities Regulatory Commission (hereinafter referred to as the "CSRC") Measures for the administration of the registration of initial public offerings on the gem (for Trial Implementation) (CSRC order [No. 167]), special provisions on the issuance and underwriting of initial public offerings on the gem (CSRC announcement [2021] No. 21, hereinafter referred to as the "special provisions"), Shenzhen Stock Exchange (hereinafter referred to as the "Shenzhen Stock Exchange") promulgated the detailed rules for the implementation of the issuance and underwriting business of initial public offering of securities on the gem of Shenzhen Stock Exchange (revised in 2021) (SZS [2021] No. 919, hereinafter referred to as the "detailed rules for the implementation of initial public offering") Detailed rules for the implementation of online IPO in Shenzhen market (SZS [2018] No. 279, hereinafter referred to as "detailed rules for the implementation of online IPO") and detailed rules for the implementation of offline IPO in Shenzhen market (SZS [2020] No. 483, hereinafter referred to as "detailed rules for the implementation of offline IPO"), The China Securities Association (hereinafter referred to as the "Securities Association") promulgated the code for underwriting initial public offering 2 under the registration system (Zhong Zheng Xie Fa [2021] No. 213), the detailed rules for the administration of offline investors in initial public offering (Zhong Zheng Xie Fa [2018] No. 142) Organize the implementation of the rules for the administration of offline investors in initial public offering under the registration system (Zhong Zheng Xie Fa [2021] No. 212) and other relevant provisions. Haitong Securities Company Limited(600837) (hereinafter referred to as " Haitong Securities Company Limited(600837) " or "sponsor (lead underwriter)") serves as the sponsor (lead underwriter) of this offering